DiaSorin (OTCMKTS:DSRLF) Upgraded to Hold by Zacks Investment Research

DiaSorin (OTCMKTS:DSRLF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Monday, Zacks.com reports.

According to Zacks, “DiaSorin S.p.A. engages in the development, production and marketing of reagent kits for in vitro diagnostics. It specializes in the provision of immunodiagnostics and molecular diagnostics solutions which serves infectious diseases, cardiac markers, bone metabolism, hepatitis and retrovirus, oncology and endocrinology clinical areas. DiaSorin S.p.A. is headquartered in Vercelli, Italy. “

Shares of DSRLF stock remained flat at $$114.75 on Monday. 5 shares of the stock were exchanged, compared to its average volume of 0. The stock’s 50 day simple moving average is $114.75. DiaSorin has a 12 month low of $80.10 and a 12 month high of $114.75.

DiaSorin Company Profile

DiaSorin S.p.A. develops, produces, and commercializes diagnostic tests in various clinical areas for hospital and private testing laboratories in the market of immunodiagnostics and molecular diagnostics. It offers immunodiagnostics products in the areas of infectious diseases; bone and mineral metabolism; endocrinology, including diabetes, thyroid function, fertility, growth, adrenal function, and gastroenterology; hypertension; oncology; stool diagnostics; autoimmunity; and cardiac and brain damages.

Recommended Story: What is net income?

Get a free copy of the Zacks research report on DiaSorin (DSRLF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DiaSorin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaSorin and related companies with MarketBeat.com's FREE daily email newsletter.